Results 21 to 30 of about 8,937,523 (396)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Journal of Clinical Oncology, 2022
PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689).
M. Provencio, R. Serna-Blasco, E. Nadal, A. Insa, M. García-Campelo, J. Casal Rubio, M. Dómine, M. Majem, D. Rodríguez-Abreu, A. Martínez-Martí, J. de Castro Carpeño, M. Cobo, G. López Vivanco, E. del Barco, R. Bernabé Caro, N. Viñolas, I. Barneto Aranda, S. Viteri, E. Pereira, A. Royuela, V. Calvo, Javier M. Martín-López, F. García-García, M. Casarrubios, Fernando Franco, E. Sánchez-Herrero, B. Massutí, A. Cruz-Bermúdez, A. Romero   +28 more
semanticscholar   +1 more source

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

New England Journal of Medicine, 2022
BACKGROUND Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits with first-line therapy with brentuximab vedotin, a CD30-directed ...
S. Ansell, J. Radford, J. Connors, M. Długosz-Danecka, W. Kim, A. Gallamini, R. Ramchandren, J. Friedberg, R. Advani, M. Hutchings, A. Evens, P. Smolewski, K. Savage, N. Bartlett, H. Eom, J. Abramson, C. Dong, F. Campana, K. Fenton, M. Puhlmann, D. Straus   +20 more
semanticscholar   +1 more source

Prognostic Outcomes and Risk Factors for Patients with Renal Cell Carcinoma and Venous Tumor Thrombus after Radical Nephrectomy and Thrombectomy: The Prognostic Significance of Venous Tumor Thrombus Level. [PDF]

, 2015
IntroductionTo evaluate the prognostic outcomes and risk factors for renal cell carcinoma (RCC) patients with venous tumor thrombus in China.Materials and methodsWe reviewed the clinical information of 169 patients who underwent radical nephrectomy and ...
He, Zhisong, Li, Xuesong, Meng, Maxwell, Song, Yi, Tang, Qi, Wang, Jin, Zhang, Qian, Zhou, Liqun   +7 more
core   +8 more sources

Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations

Опухоли женской репродуктивной системы, 2021
Background. According to randomized clinical trial SOLO1 olaparib statistically significantly improves progression-free survival versus placebo as a maintenance monotherapy in patients aged 18 and over with newly diagnosed advanced ovarian cancer with ...
N. A. Avxentyev, S. V. Khokhlova, M. Yu. Frolov, A. S. Makarov   +3 more
doaj   +1 more source

The advanced lung cancer inflammation index is the optimal inflammatory biomarker of overall survival in patients with lung cancer

Journal of Cachexia, Sarcopenia and Muscle, 2022
Malnutrition and systemic inflammatory responses are associated with poor overall survival (OS) in lung cancer patients, but it remains unclear which biomarkers are better for predicting their prognosis.
Mengmeng Song, Qi Zhang, C. Song, Tong Liu, Xi Zhang, Guo-tian Ruan, M. Tang, Hailun Xie, He-yang Zhang, Yi-zhong Ge, Xiangrui Li, Kang Zhang, Ming Yang, Qinqin Li, Xiaoyue Liu, Shiqi Lin, Yu Xu, Hongxia Xu, Kunhua Wang, Wei Li, Han-ping Shi   +20 more
semanticscholar   +1 more source

Prognostic value of peripheral blood lymphocyte subsets in patients with solid cancers: a retrospective study [PDF]

Archives of the Balkan Medical Union, 2021
Introduction. Lymphocyte subsets are important in regulating immunity and specific killing of tumour cells and appear to be strongly associated with the development of solid tumours.
Marieta-Elena PANAIT, Antonela BUSCA, Ana-Maria COMAN, Mariana SAULEA, Lucica-Madalina BOLOVAN   +4 more
doaj   +1 more source

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. [PDF]

, 2020
BackgroundTransforming growth factor beta (TGF-β) signalling is involved in the development of hepatocellular carcinoma (HCC). We followed changes in biomarkers during treatment of patients with HCC with the TGF-βRI/ALK5 inhibitor galunisertib ...
Benhadji, Karim A, Cleverly, Ann, Estrem, Shawn T, Faivre, Sandrine, Gane, Ed, Giannelli, Gianluigi, Kelley, Robin K, Lahn, Michael M, Man, Michael, Paradis, Valerie, Raymond, Eric, Santoro, Armando, Smith, Claire, Wang, Shuaicheng   +13 more
core   +2 more sources

Outcome of match related allogeneic stem cell transplantation procedures performed from 2004 till 2011

Experimental Hematology & Oncology, 2012
We present our initial experience of allogeneic stem cell transplant procedure performed between April 2004 and August 2011 for various haematological disorders.
Ali Natasha, Adil Salman, Shaikh Mohammad, Moosajee Munira, Masood Nehal   +4 more
doaj   +1 more source

Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework

CPT: Pharmacometrics & Systems Pharmacology, 2021
The objectives of the study were to use tumor size data from 10 phase II/III atezolizumab studies across five solid tumor types to estimate tumor growth inhibition (TGI) metrics and assess the impact of TGI metrics and baseline prognostic factors on ...
Phyllis Chan, Mathilde Marchand, Kenta Yoshida, Shweta Vadhavkar, Nina Wang, Alyse Lin, Benjamin Wu, Marcus Ballinger, Nitzan Sternheim, Jin Y. Jin, René Bruno   +10 more
doaj   +1 more source

Extraskeletal myxoid chondrosarcoma: Clinical features and overall survival

Cancer Treatment and Research Communications, 2022
Introduction: : Extraskeletal myxoid chondrosarcoma is a rare form of soft tissue sarcoma characterized by a unique chromosomal translocation involving the NR4A3 gene on chromosome 9.
Jeffrey Mark Brown, Kyla Rakoczy, Juan Pretell-Mazzini   +2 more
doaj   +1 more source